These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 3295122)

  • 61. Quantitative magnetic resonance imaging in multiple sclerosis: the effect of high dose intravenous methylprednisolone.
    Kesselring J; Miller DH; MacManus DG; Johnson G; Milligan NM; Scolding N; Compston DA; McDonald WI
    J Neurol Neurosurg Psychiatry; 1989 Jan; 52(1):14-7. PubMed ID: 2709033
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Hyperbaric oxygen and multiple sclerosis: short-term results of a placebo-controlled, double-blind trial.
    Barnes MP; Bates D; Cartlidge NE; French JM; Shaw DA
    Lancet; 1985 Feb; 1(8424):297-300. PubMed ID: 2857361
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [The comparison of the effectiveness of treatment of multiple sclerosis relapse with high doses of methylprednisolone, alpha-24 corticotropin and cyclophosphamide].
    Paradowski B; Gruszka E; Pokryszko A
    Pol Merkur Lekarski; 1999 Jun; 6(36):305-7. PubMed ID: 10481540
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Randomised double blind controlled trial of cyclosporin in multiple sclerosis.
    Rudge P; Koetsier JC; Mertin J; Mispelblom Beyer JO; Van Walbeek HK; Clifford Jones R; Harrison J; Robinson K; Mellein B; Poole T
    J Neurol Neurosurg Psychiatry; 1989 May; 52(5):559-65. PubMed ID: 2659736
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Posturography in MS patients treated with high dose methylprednisolone.
    Gandelman-Marton R; Arlazoroff A; Dvir Z
    Neurol Res; 2016 Jul; 38(7):570-4. PubMed ID: 27151095
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A randomised controlled trial comparing rehabilitation against standard therapy in multiple sclerosis patients receiving intravenous steroid treatment.
    Craig J; Young CA; Ennis M; Baker G; Boggild M
    J Neurol Neurosurg Psychiatry; 2003 Sep; 74(9):1225-30. PubMed ID: 12933923
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Improvement in motor evoked potentials and clinical course post-steroid therapy in multiple sclerosis.
    Salle JY; Hugon J; Tabaraud F; Boulesteix JM; Vallat JM; Dumas M; Poser CM
    J Neurol Sci; 1992 Apr; 108(2):184-8. PubMed ID: 1517750
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Randomized controlled trial of high-dose peroral methylprednisolone in attacks of multiple sclerosis].
    Sellebjerg F; Frederiksen JL; Nielsen PM; Olesen J
    Ugeskr Laeger; 1999 Nov; 161(48):6625-9. PubMed ID: 10643347
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Double-blind, placebo-controlled pilot randomized trial of methylprednisolone infusion in pediatric acute respiratory distress syndrome.
    Drago BB; Kimura D; Rovnaghi CR; Schwingshackl A; Rayburn M; Meduri GU; Anand KJ
    Pediatr Crit Care Med; 2015 Mar; 16(3):e74-81. PubMed ID: 25634565
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis.
    Bornstein MB; Miller A; Slagle S; Weitzman M; Crystal H; Drexler E; Keilson M; Merriam A; Wassertheil-Smoller S; Spada V
    N Engl J Med; 1987 Aug; 317(7):408-14. PubMed ID: 3302705
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Reversible impaired memory induced by pulsed methylprednisolone in patients with MS.
    Uttner I; Müller S; Zinser C; Maier M; Süssmuth S; Claus A; Ostermann B; Elitok E; Ecker D; Brettschneider J; Gold R; Tumani H
    Neurology; 2005 Jun; 64(11):1971-3. PubMed ID: 15955958
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Confavreux C; O'Connor P; Comi G; Freedman MS; Miller AE; Olsson TP; Wolinsky JS; Bagulho T; Delhay JL; Dukovic D; Truffinet P; Kappos L;
    Lancet Neurol; 2014 Mar; 13(3):247-56. PubMed ID: 24461574
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A placebo-controlled trial of isoprinosine in patients with multiple sclerosis.
    Milligan NM; Miller DH; Compston DA
    J Neurol Neurosurg Psychiatry; 1994 Feb; 57(2):164-8. PubMed ID: 7510330
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Efficacy of combination therapy with erythropoietin and methylprednisolone in clinical recovery of severe relapse in multiple sclerosis.
    Najmi Varzaneh F; Najmi Varzaneh F; Azimi AR; Rezaei N; Sahraian MA
    Acta Neurol Belg; 2014 Dec; 114(4):273-8. PubMed ID: 24604685
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study.
    van Diemen HA; Polman CH; van Dongen TM; van Loenen AC; Nauta JJ; Taphoorn MJ; van Walbeek HK; Koetsier JC
    Ann Neurol; 1992 Aug; 32(2):123-30. PubMed ID: 1510353
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Methylprednisolone in multiple sclerosis: a comparative dose study.
    Bindoff L; Lyons PR; Newman PK; Saunders M
    J Neurol Neurosurg Psychiatry; 1988 Aug; 51(8):1108-9. PubMed ID: 3063777
    [No Abstract]   [Full Text] [Related]  

  • 77. ω-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial.
    Torkildsen O; Wergeland S; Bakke S; Beiske AG; Bjerve KS; Hovdal H; Midgard R; Lilleås F; Pedersen T; Bjørnarå B; Dalene F; Kleveland G; Schepel J; Olsen IC; Myhr KM
    Arch Neurol; 2012 Aug; 69(8):1044-51. PubMed ID: 22507886
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment.
    Warren KG; Catz I; Ferenczi LZ; Krantz MJ
    Eur J Neurol; 2006 Aug; 13(8):887-95. PubMed ID: 16879301
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial.
    Mazlumzadeh M; Hunder GG; Easley KA; Calamia KT; Matteson EL; Griffing WL; Younge BR; Weyand CM; Goronzy JJ
    Arthritis Rheum; 2006 Oct; 54(10):3310-8. PubMed ID: 17009270
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study.
    Bracken MB; Shepard MJ; Collins WF; Holford TR; Young W; Baskin DS; Eisenberg HM; Flamm E; Leo-Summers L; Maroon J
    N Engl J Med; 1990 May; 322(20):1405-11. PubMed ID: 2278545
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.